Details

Autor(en) / Beteiligte

• Boettiger, David C.
• Muktiarti, Dina
• Kurniati, Nia
• Truong, Khanh H.
• Saghayam, Suneeta
• Ly, Penh Sun
• Hansudewechakul, Rawiwan
• Van Nguyen, Lam
• Do, Viet Chau
• Sudjaritruk, Tavitiya
• Lumbiganon, Pagakrong
• Chokephaibulkit, Kulkanya
• Bunupuradah, Torsak
• Yusoff, Nik Khairulddin Nik
• Wati, Dewi Kumara
• Razali, Kamarul Azahar Mohd
• Fong, Moy Siew
• Nallusamy, Revathy A.
• Sohn, Annette H.
• Kariminia, Azar

Titel

Early Height and Weight Changes in Children Using Cotrimoxazole Prophylaxis With Antiretroviral Therapy

Ist Teil von

• Clinical infectious diseases, 2016-11, Vol.63 (9), p.1236-1244

Ort / Verlag

United States: Oxford University Press

Erscheinungsjahr

2016

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Background. The growth benefits of cotrimoxazole during early antiretroviral therapy (ART) are not well characterized. Methods. Individuals enrolled in the Therapeutics Research, Education, and AIDS Training in Asia Pediatric HIV Observational Database were included if they started ART at ages 1 month–14 years and had both height and weight measurements available at ART initiation (baseline). Generalized estimating equations were used to identify factors associated with change in height-for-age z-score (HAZ), follow-up HAZ ≥ −2, change in weight-for-age z-score (WAZ), and follow-up WAZ ≥ −2. Results. A total of 3217 children were eligible for analysis. The adjusted mean change in HAZ among cotrimoxazole and non-cotrimoxazole users did not differ significantly over the first 24 months of ART. In children who were stunted (HAZ < −2) at baseline, cotrimoxazole use was not associated with a follow-up HAZ ≥ −2. The adjusted mean change in WAZ among children with a baseline CD4 percentage (CD4%) >25% became significantly different between cotrimoxazole and non-cotrimoxazole users after 6 months of ART and remained significant after 24 months (overall P < .01). Similar changes in WAZ were observed in those with a baseline CD4% between 10% and 24% (overall P < .01). Cotrimoxazole use was not associated with a significant difference in followup WAZ in children with a baseline CD4% <10%. In those underweight (WAZ < −2) at baseline, cotrimoxazole use was associated with a follow-up WAZ ≥ −2 (adjusted odds ratio, 1.70 vs not using cotrimoxazole [95% confidence interval, 1.28–2.25], P < .01). This association was driven by children with a baseline CD4% ≥10%. Conclusions. Cotrimoxazole use is associated with benefits to WAZ but not HAZ during early ART in Asian children.